RZLT Quote, Financials, Valuation and Earnings

Janux Therapeutics has a net margin of -- compared to Rezolute's net margin of -6391.57%. Rezolute's return on equity of -- beat Janux Therapeutics's return on equity of -11.37%.

Rezolute has a consensus price target of $9.67, signalling upside risk potential of 159.48%. On the other hand Janux Therapeutics has an analysts' consensus of -- which suggests that it could grow by 66.1%. Given that Rezolute has higher upside potential than Janux Therapeutics, analysts believe Rezolute is more attractive than Janux Therapeutics.

Rezolute has a beta of 1.011, which suggesting that the stock is 1.093% more volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rezolute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Rezolute quarterly revenues are --, which are smaller than Janux Therapeutics quarterly revenues of $439K. Rezolute's net income of -$15.4M is higher than Janux Therapeutics's net income of -$28.1M. Notably, Rezolute's price-to-earnings ratio is -- while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute is -- versus 216.51x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Rezolute's net margin of -49.65%. Rezolute's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rezolute has a consensus price target of $9.67, signalling upside risk potential of 159.48%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Rezolute, analysts believe NovaBay Pharmaceuticals is more attractive than Rezolute.

Rezolute has a beta of 1.011, which suggesting that the stock is 1.093% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Rezolute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rezolute quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rezolute's net income of -$15.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rezolute's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Rezolute's net margin of -2357.27%. Rezolute's return on equity of -- beat Palatin Technologies's return on equity of --.

Rezolute has a consensus price target of $9.67, signalling upside risk potential of 159.48%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Rezolute, analysts believe Palatin Technologies is more attractive than Rezolute.

Rezolute has a beta of 1.011, which suggesting that the stock is 1.093% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Rezolute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Rezolute quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Rezolute's net income of -$15.4M is lower than Palatin Technologies's net income of -$7.8M. Notably, Rezolute's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -- compared to Rezolute's net margin of 3.88%. Rezolute's return on equity of -- beat TransMedics Group's return on equity of 19.83%.

Rezolute has a consensus price target of $9.67, signalling upside risk potential of 159.48%. On the other hand TransMedics Group has an analysts' consensus of $102.00 which suggests that it could grow by 62.94%. Given that Rezolute has higher upside potential than TransMedics Group, analysts believe Rezolute is more attractive than TransMedics Group.

Rezolute has a beta of 1.011, which suggesting that the stock is 1.093% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.81%.

Rezolute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rezolute pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Rezolute quarterly revenues are --, which are smaller than TransMedics Group quarterly revenues of $108.8M. Rezolute's net income of -$15.4M is lower than TransMedics Group's net income of $4.2M. Notably, Rezolute's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 66.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rezolute is -- versus 5.40x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.